AbbVie Closes $10.9B Apogee Deal, Reaffirms 2026 EPS Outlook
ABBV sits 38% above its 52-week low of $190.75.
Summary
The $10.9B acquisition of Apogee Therapeutics is complete, adding two late-stage immunology assets. 2026 EPS guidance was reaffirmed while the deal's near-term dilution was quantified.
Key Events · M&A and Partnerships · ABBV
-
Apogee Acquisition Completed
The $10.9 billion all-cash acquisition of Apogee Therapeutics closed on September 3, 2026, at $135.11 per share.
-
EPS Impact Quantified
Adjusted EPS will be diluted by $0.14 in 2026 and $0.46 in 2027, with accretion expected beginning in 2032.
-
2026 Guidance Reaffirmed
Full-year 2026 adjusted EPS guidance of $13.87-$14.07 and Q3 guidance of $3.84-$3.88 were reaffirmed, both including the acquisition's impact.
-
Pipeline Expansion
Zumilokibart (Phase 2-ready IL-13 antibody for atopic dermatitis) and APG273 (IL-13/TSLP combination for asthma) join the immunology portfolio.
Analysis · ABBV · Life Sciences
The $10.9 billion acquisition of Apogee Therapeutics has closed, bringing late-stage immunology assets zumilokibart and APG273 into the pipeline. While the deal's completion was expected since its June announcement, the filing adds new material details: adjusted EPS will be diluted by $0.14 in 2026 and $0.46 in 2027, with accretion not expected until 2032. Full-year and Q3 2026 EPS guidance was reaffirmed, signaling that the near-term impact is manageable within existing forecasts.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.1% of the 2014 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABBV was trading at $262.44 on NYSE in the Life Sciences sector, with a market capitalization of approximately $462.5B. The 52-week trading range was $190.75 to $267.47. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.